EUROATLANTIC-AIRWAYS
euroAtlantic Airways – Transportes Aereos S.A. (“euroAtlantic”, “EAA” or “the Company”), the Portuguese aircraft wet-leasing and charter business, today announces that Stewart Higginson has been appointed CEO and Chair of euroAtlantic and will be joined by the highly experienced management team of Mário Alvim, Lourenço Gomes and João Nunes, who will complete the Board.
Alongside the Board changes, Njord I-Jet Aviation S.A.R.L ("Njord I-Jet"), which owns a controlling interest in EAA, has committed further funding to the Company, demonstrating Njord I-Jet’s confidence in the positive outlook for the business and positioning EAA for growth as it enters the next important phase in its development. The management team’s focus will be on optimising performance improvements and expanding the Company’s current fleet of five Boeing aircraft to meet demand and improving its market-leading ACMI and charter services.
Stewart has deep experience of delivering operational performance improvements in companies across multiple sectors. He has been an Operating Partner with Njord Partners since February 2015, during which time he has held a number of key leadership roles including CEO of Geoquip Marine and CEO of Nuova Deroma, and has held a number of board roles as both a director and Chair. Stewart has received multiple awards and nominations for his instrumental roles in corporate restructurings and turnarounds, including International Turnaround of the Year for DeepOcean in 2012, and for Solidal in 2020. Stewart was a Director at Alix Partners for nine years and is a member of the UK Institute for Turnaround.
Mário, Lourenço and João collectively have more than 40 years’ experience at euroAtlantic and c. 100 years of experience in the aviation industry. Mário is euroAtlantic’s Chief Pilot and has been at the Company since its founding year (1993). He started his career at Air Atlantis. Lourenço is Chief Operations Officer. He joined the Company in March 2016, having previously held management positions at TAP. He started his career as a pilot for Portugalia Airlines, TAP Portugal and Emirates. João rejoined euroAtlantic in March 2023, after having previously worked for euroAtlantic between 2004 and 2008 and holds the role of Accountable Manager. His 25+ year career in aviation includes experienced roles at TAP, Netjets and JetCapitalAviation, where he was Airworthiness Manager and Deputy Accountable Manager.
Njord I-Jet is wholly owned by funds managed by Njord Partners LLP, a long-term investor in the Western European middle-market with significant and proven expertise in successful turnarounds. Njord Partners has assets under management in excess of €1 billion, providing capital solutions and actively facilitating strategic and operational enhancements within its portfolio companies to drive value for all stakeholders.
Stewart Higginson, euroAtlantic CEO and Chair, commented: “I am delighted to be joining euroAtlantic, where I look forward to working with the new Board to drive the next phase of euroAtlantic’s growth and deliver a world-class ACMI and charter solutions business.”
Jakob Kjellberg, Co-Founder and Co-Portfolio Manager at Njord Partners, said: “We are excited about the future prospects of well capitalized EAA under new leadership. The Company couldn’t have anyone better than Stewart and the team to lead it through its ongoing transformation and deliver high quality, cost effective and flexible services to our valued customers. Stewart’s experience in optimising operations and performance is second-to-none and we know the business will thrive with him in this new role.”
About euroAtlantic Airways
euroAtlantic Airways is a Portuguese airline specializing in ACMI and charter solutions, operating a diverse fleet of aircraft. Headquartered in Carnaxide and based at Lisbon Airport, it offers charter services, wet-lease, and Ad-Hoc flights across the globe, and has served 719 Airports in 176 countries in 30 years of operations. euroAtlantic Airways was acquired a consortium including Njord Partners, in November 2019.
To find out more visit: https://www.euroatlantic.pt/en/quem-somos/
About Njord Partners
Njord Partners is a European special situations investment manager and provider of long-term flexible capital solutions, primarily to family-owned businesses. Established in 2013, Njord Partners has invested in 24 businesses and manages capital in excess of €1 billion. The Njord team has led turnarounds of over 25 companies located in 9 different jurisdictions, spanning 8 separate industries.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417583477/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom